In this issue:
- Circulating tumour DNA-guided adjuvant therapy
- Pembrolizumab cost-effectiveness for colorectal cancer
- Fruquintinib plus PD-1 inhibitors for metastatic colorectal cancer
- Anlotinib for RAS/BRAF wild-type metastatic colorectal cancer
- PD-1 blockade in dMMR locally advanced rectal cancer
- Exercise and colorectal cancer survival
- 18F-FDG-PET measurement of chemoradiotherapy response in anal cancer
- Radiotherapy + raltitrexed and irinotecan for unresectable recurrent colorectal cancer
- Outcomes in patients with delayed surveillance colonoscopy
- Cost-effectiveness of tailored colonoscopic surveillance in Lynch syndrome
Please login below to download this issue (PDF)